Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer-Reference-Cited by-同舟云学术

Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer

Published:2018-08-22 Issue:12 Volume:37 Page:2565-2571
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Buelens Sarah^ORCID,De Bleser Elise,Dhondt Bert,Verla Wesley,Decaestecker Karel,Ost Piet,Fonteyne Valérie,De Man Kathia,Standaert Chloë,Rottey Sylvie,Lumen Nicolaas

Funder

Universitair Ziekenhuis Gent

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-018-2449-6.pdf

Reference19 articles.

1. Huggins C (1941) Studies on prostatic cancer. Arch Surg 43(2):209. https://doi.org/10.1001/archsurg.1941.01210140043004

2. Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002

3. James ND, Spears MR, Clarke NW et al (2015) Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67(6):1028–1038. https://doi.org/10.1016/j.eururo.2014.09.032

4. Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746. https://doi.org/10.1056/NEJMoa1503747

5. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177. https://doi.org/10.1016/S0140-6736(15)01037-5

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone‐sensitive prostate cancer;The Prostate;2024-07-10

2. Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort;Cancers;2023-09-29

3. The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome;International Journal of Molecular Sciences;2023-09-22

4. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis;Clinical Genitourinary Cancer;2023-09

5. Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor;Archivos Españoles de Urología;2023